Abstract
The live, attenuated shingles (herpes zoster) vaccine Zostavax® is approved in the EU for use in the prevention of herpes zoster and postherpetic neuralgia in adults aged ≥50 years. In adults aged ≥60 years, zoster vaccine reduced the burden of illness associated with herpes zoster, with reductions in the incidence of postherpetic neuralgia and herpes zoster, according to the results of the Shingles Prevention Study. Results of subsequent Short- and Long-Term Persistence Substudies indicate that the efficacy of zoster vaccine is maintained in the longer term, albeit with a gradual decline over time. In the Zostavax Efficacy and Safety Trial, zoster vaccine reduced the incidence of herpes zoster in adults aged 50–59 years. Findings of these studies are supported by the results of large, retrospective, cohort studies. Zoster vaccine was generally well tolerated, with injection-site adverse events being the most commonly reported adverse events. In conclusion, zoster vaccine provides an important opportunity to reduce the burden of illness associated with herpes zoster by reducing the incidence of herpes zoster and postherpetic neuralgia.
Similar content being viewed by others
References
Drolet M, Oxman MN, Levin MJ, et al. Vaccination against herpes zoster in developed countries: state of the evidence. Hum Vaccin Immunother. 2013;9(5).
Fashner J, Bell AL. Herpes zoster and postherpetic neuralgia: prevention and management. Am Fam Phys. 2011;83(12):1432–7.
Li H-T, Lu S, Liu J-M. Herpes zoster vaccination in people aged 50–59 years. Clin Infect Dis. 2012;54(7):929–30.
Pinchinat S, Cebrián-Cuenca AM, Bricout H, et al. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis. 2013;13(1):170.
Yawn BP, Saddier P, Wollan PC, et al. A population-based study of the incidence and complication rates of herpes zoster before zoster vaccine introduction. Mayo Clin Proc. 2007;82(11):1341–9.
Zin CS, Nissen LM, Smith MT, et al. An update on the pharmacological management of post-herpetic neuralgia and painful diabetic neuropathy. CNS Drugs. 2008;22(5):417–42.
Johnson RW, Wasner G, Saddier P, et al. Herpes zoster and postherpetic neuralgia: optimizing management in the elderly patient. Drugs Aging. 2008;25(12):991–1006.
European Medicines Agency. Zostavax (shingles [herpes zoster] vaccine (live]): EU summary of product characteristics. 2013. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000674/WC500053462.pdf. Accessed 11 Jun 2013.
Sanofi Pasteur MSD Limited. Varivax (varicella vaccine [live]): UK summary of product characteristics. 2013. http://www.medicines.org.uk/emc/medicine/15264/SPC/VARIVAX/. Accessed 11 Jun 2013.
Gilderman LI, Lawless JF, Nolen TM, et al. A double-blind, randomized, controlled, multicenter safety and immunogenicity study of a refrigerator-stable formulation of Zostavax. Clin Vaccine Immunol. 2008;15(2):314–9.
Sanford M, Keating GM. Zoster vaccine (Zostavax®): a review of its use in preventing herpes zoster and postherpetic neuralgia in older adults. Drugs Aging. 2010;27(2):159–76.
Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50–59 years. Clin Infect Dis. 2012;54(7):922–8.
Levin MJ, Oxman MN, Zhang JH, et al. Varicella-zoster virus-specific immune responses in elderly recipients of a herpes zoster vaccine. J Infect Dis. 2008;197(6):825–35.
Levin MJ, Schmader KE, Zerbe GO, et al. Safety, tolerability, and immunogenicity of a booster dose of zoster vaccine (ZV) administered ≥10 years after a first dose compared with a first dose of ZV [abstract]. 20th IAGG World Congress of Gerontology and Geriatrics; 23–27 Jun 2013; Seoul.
Merck. Safety, tolerability, and immunogenicity of a booster dose of zoster vaccine, live (V211-029 AM1) [ClinicalTrials.gov identifier NCT01245751] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT01245751. Accessed 12 Jun 2013.
Parrino J, Marquez F, Fisher CL, et al. Safety, tolerability, and immunogenicity of zoster vaccine in patients on chronic/maintenance corticosteroids [abstract]. Arthritis Rheum. 2011;63(Suppl 10):2071.
Wasan S, Berg A, Liang YM, et al. Immune response and safety of herpes zoster vaccine in IBD patients on methotrexate or thiopurines [abstract no. 1651]. Am J Gastroenterol. 2012;107(Suppl 1):S668.
Benson C, Hua L, Andersen J, et al. Zostavax is generally safe and immunogenic in HIV + adults virologically suppressed on ART: results of a phase 2, randomized, double-blind, placebo- controlled trial [abstract no. 96]. 19th Conference on Retroviruses and Opportunistic Infections; 5–8 Mar 2012; Seattle (WA).
National Institute of Allergy and Infectious Diseases. Live zoster vaccine in HIV-infected adults on antiretroviral therapy [ClinicalTrials.gov identifier NCT00851786] US National Institutes of Health, ClinicalTrials.gov. 2013. http://www.clinicaltrials.gov/ct2/show/NCT00851786. Accessed 11 Jun 2013.
Weinberg A, Zhang JH, Oxman MN, et al. Varicella-zoster virus-specific immune responses to herpes zoster in elderly participants in a trial of a clinically effective zoster vaccine. J Infect Dis. 2009;200(7):1068–77.
Irwin MR, Levin MJ, Laudenslager ML, et al. Varicella zoster virus-specific immune responses to a herpes zoster vaccine in elderly recipients with major depression and the impact of antidepressant medications. Clin Infect Dis. 2013;56(8):1085–93.
Mills R, Tyring SK, Levin MJ, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects with a history of herpes zoster. Vaccine. 2010;28(25):4204–9.
Arnou R, Fiquet A, Thomas S, et al. Immunogenicity and safety of Zostavax® approaching expiry potency in individuals aged ≥50 years. Hum Vaccin. 2011;7(10):1060–5.
Kerzner B, Murray AV, Cheng E, et al. Safety and immunogenicity profile of the concomitant administration of Zostavax and inactivated influenza vaccine in adults aged 50 and older. J Am Geriatr Soc. 2007;55(10):1499–507.
Vermeulen JN, Lange JMA, Tyring SK, et al. Safety, tolerability, and immunogenicity after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age. Vaccine. 2012;30(5):904–10.
MacIntyre CR, Egerton T, McCaughey M, et al. Concomitant administration of zoster and pneumococcal vaccines in adults ≥60 years old. Hum Vaccin. 2010;6(11):894–902.
Vesikari T, Hardt R, Rümke HC, et al. Immunogenicity and safety of a live attenuated shingles (herpes zoster) vaccine (Zostavax®) in individuals aged ≥70 years: a randomized study of a single dose versus two different two-dose schedules. Hum Vaccin Immunother. 2013;9:4.
Sutradhar SC, Wang WWB, Schlienger K, et al. Comparison of the levels of immunogenicity and safety of Zostavax in adults 50 to 59 years old and in adults 60 years old or older. Clin Vaccine Immunol. 2009;16(5):646–52.
Oxman MN, Levin MJ, Johnson GR, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271–84.
Schmader KE, Oxman MN, Levin MJ, et al. Persistence of the efficacy of zoster vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy. Clin Infect Dis. 2012;55(10):1320–8.
Langan SM, Smeeth L, Margolis DJ, et al. Herpes zoster vaccine effectiveness against incident herpes zoster and post-herpetic neuralgia in an older US population: a cohort study. PLoS Med. 2013;10(4):e1001420.
Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011;305(2):160–6.
Tseng HF, Chi M, Smith N, et al. Herpes zoster vaccine and the incidence of recurrent herpes zoster in an immunocompetent elderly population. J Infect Dis. 2012;206(2):190–6.
Tseng HF, Smith N, Sy LS, et al. Evaluation of the incidence of herpes zoster after concomitant administration of zoster vaccine and polysaccharide pneumococcal vaccine. Vaccine. 2011;29(20):3628–32.
Zhang J, Delzell E, Xie F, et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther. 2011;13(5):R174.
Zhang J, Xie F, Delzell E, et al. Association between vaccination for herpes zoster and risk of herpes zoster infection among older patients with selected immune-mediated diseases. JAMA. 2012;308(1):43–9.
Schmader KE, Johnson GR, Saddier P, et al. Effect of a zoster vaccine on herpes zoster-related interference with functional status and health-related quality-of-life measures in older adults. J Am Geriatr Soc. 2010;58(9):1634–41.
Merck and Co. Inc. Zostavax® (zoster vaccine live) [refrigerator stable] suspension for subcutaneous injection: US prescribing information. 2011. http://www.fda.gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM285015.pdf. Accessed 28 May 2013.
Simberkoff MS, Arbeit RD, Johnson GR, et al. Safety of herpes zoster vaccine in the Shingles Prevention Study: a randomized trial. Ann Intern Med. 2010;152(9):545–54.
Morrison VA, Oxman MN, Levin MJ, et al. Safety of zoster vaccine in elderly adults following documented herpes zoster. J Infect Dis. 2013;. doi:10.1093/infdis/jit182.
Murray AV, Reisinger KS, Kerzner B, et al. Safety and tolerability of zoster vaccine in adults ≥60 years old. Hum Vaccin. 2011;7(11):1130–6.
Tseng HF, Liu A, Sy L, et al. Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. J Intern Med. 2012;271(5):510–20.
Baxter R, Tran TN, Hansen J, et al. Safety of Zostavax™: a cohort study in a managed care organization. Vaccine. 2012;30(47):6636–41.
Annemans L, Bresse X, Gobbo C, et al. Health economic evaluation of a vaccine for the prevention of herpes zoster (shingles) and post-herpetic neuralgia in adults in Belgium. J Med Econ. 2010;13(3):537–51.
Bilcke J, Marais C, Ogunjimi B, et al. Cost-effectiveness of vaccination against herpes zoster in adults aged over 60 years in Belgium. Vaccine. 2012;30(3):675–84.
van Hoek AJ, Gay N, Melegaro A, et al. Estimating the cost-effectiveness of vaccination against herpes zoster in England and Wales. Vaccine. 2009;27(9):1454–67.
Moore L, Remy V, Martin M, et al. A health economic model for evaluating a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in the UK. Cost Effect Resour Allocat. 2010;8(7).
van Lier A, van Hoek AJ, Opstelten W, et al. Assessing the potential effects and cost-effectiveness of programmatic herpes zoster vaccination of elderly in the Netherlands. BMC Health Serv Res. 2010;10:237.
de Boer PT, Pouwels KB, Cox JM, et al. Cost-effectiveness of vaccination of the elderly against herpes zoster in The Netherlands. Vaccine. 2013;31(9):1276–83.
Szucs TD, Kressig RW, Papageorgiou M, et al. Economic evaluation of a vaccine for the prevention of herpes zoster and post-herpetic neuralgia in older adults in Switzerland. Hum Vaccin. 2011;7(7):749–56.
Levin MJ. Immune senescence and vaccines to prevent herpes zoster in older persons. Curr Opin Immunol. 2012;24(4):494–500.
Oxman MN, Gershon AA, Poland GA. Zoster vaccine recommendations: the importance of using a clinically valid correlate of protection. Vaccine. 2011;29(20):3625–7.
Drolet M, Brisson M, Levin MJ, et al. A prospective study of the herpes zoster severity of illness. Clin J Pain. 2010;26(8):656–66.
White RR, Lenhart G, Singhal PK, et al. Incremental 1-year medical resource utilization and costs for patients with herpes zoster from a set of US health plans. Pharmacoeconomics. 2009;27(9):781–92.
Merck. Zostavax™ (zoster vaccine live) long-term effectiveness study (V211-024) [ClinicalTrials.gov identifier NCT01600079] US National Institutes of Health, ClinicalTrials.gov. 2012. http://www.clinicaltrials.gov/ct2/show/NCT01600079. Accessed 11 Jun 2013.
Johnson RW, Bouhassira D, Kassianos G, et al. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8:37.
Drolet M, Brisson M, Schmader KE, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Can Med Assoc J. 2010;182(16):1731–6.
Harpaz R, Nagel MA, Schmader K, et al. Roundtable on postherpetic neuralgia: what, why, how long, and what’s next? Popul Health Manag. 2012;15(6):385–90.
Ultsch B, Siedler A, Rieck T, et al. Herpes zoster in Germany: quantifying the burden of disease. BMC Infect Dis. 2011;11:173.
Gauthier A, Breuer J, Carrington D, et al. Epidemiology and cost of herpes zoster and post-herpetic neuralgia in the United Kingdom. Epidemiol Infect. 2009;137(1):38–47.
Bilcke J, Ogunjimi B, Hulstaert F, et al. Estimating the age-specific duration of herpes zoster vaccine protection: a matter of model choice? Vaccine. 2012;30(17):2795–800.
Gilden D. Efficacy of live zoster vaccine in preventing zoster and postherpetic neuralgia. J Intern Med. 2011;269(5):496–506.
Lu P-J, Euler GL, Harpaz R. Herpes zoster vaccination among adults aged 60 years and older, in the U.S., 2008. Am J Prev Med. 2011;40(2):e1–6.
Elkin Z, Cohen EJ, Goldberg JD, et al. Studying physician knowledge, attitudes, and practices regarding the herpes zoster vaccine to address perceived barriers to vaccination. Cornea. 2013;32(7):976–81.
Javed S, Javed F, Mays RM, et al. Herpes zoster vaccine awareness among people = 50 years of age and its implications on immunization. Dermatol Online J. 2012;18(8):2.
Hurley LP, Lindley MC, Harpaz R, et al. Barriers to the use of herpes zoster vaccine. Ann Intern Med. 2010;152(9):555–60.
Gerberding J, Yawn BP. Discussing the zoster vaccine: an interview with Julie Gerberding, president of Merck vaccines. Popul Health Manag. 2012;15(6):382–4.
European Medicines Agency. Zostavax (zoster vaccine): scientific discussion—variation. 2007. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000674/human_med_001185.jsp&mid=WC0b01ac058001d124. Accessed 29 May 2013.
Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2013. Ann Intern Med. 2013;158(3):191–9.
National Health Service. The NHS vaccination schedule. 2013. http://www.nhs.uk/Conditions/vaccinations/Pages/vaccination-schedule-age-checklist.aspx. Accessed 11 Jun 2013.
Sanofi Pasteur MSD. UK first major European country to run Zostavax nationwide shingles vaccination programme [media release]. 2013. http://www.spmsd.com/news/uk-first-major-european-country-to-run-zostavax-nationwide-shingles-vaccination-programme/. Accessed 11 Jun 2013.
Disclosure
The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made by the author on the basis of scientific and editorial merit.
Author information
Authors and Affiliations
Corresponding author
Additional information
The manuscript was reviewed by: G. Icardi, Department of Health Sciences, University of Genoa, Genoa, Italy; C. A. Kauffman, Division of Infectious Diseases, Veterans Affairs Ann Arbor Healthcare System, University of Michigan Medical School, Ann Arbor, MI, USA; M. J. Levin, Division of Infectious Diseases, Children’s Hospital Colorado and University of Colorado, School of Medicine, Aurora, CO, USA; V. A. Morrison, Veterans Affairs Medical Center and University of Minnesota, Minneapolis, MN, USA; T. Vesikari, Vaccine Research Center, University of Tampere Medical School, Tampere, Finland.
Rights and permissions
About this article
Cite this article
Keating, G.M. Shingles (Herpes Zoster) Vaccine (Zostavax®): A Review of Its Use in the Prevention of Herpes Zoster and Postherpetic Neuralgia in Adults Aged ≥50 Years. Drugs 73, 1227–1244 (2013). https://doi.org/10.1007/s40265-013-0088-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40265-013-0088-1